Skip to main content

Table 2 Characteristics of Analyzed Population at Year 5 (n = 5,320) with 500 deaths at up to 10 years of follow-up

From: Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study

 

N

%

Person-Years of Follow-up

Deaths per 1,000 Person Years

Sex

    

   Female

1,992

37.4

17,221

9.4

   Male

3,328

62.6

28,587

11.8

Age Group, years

    

   35-39

25

0.5

214

9.3

   40-49

1,708

32.1

14,995

4.7

   50-59

2,436

45.8

20,954

11.4

   60+

1,151

21.6

9,644

19.7

Body Mass Index, kg/m2

    

   < 25

2,536

47.7

21,849

10.7

   25- 30

2,098

39.4

18,075

10.6

   > = 30

686

12.9

5,884

12.7

Education (years)

    

   < 12

639

12.0

5,496

14.0

   12

1,595

30.0

13,735

11.5

   > 12

3,086

58.0

26,577

10.0

Race

    

   White

5,136

96.5

44,226

10.6

   Non-White

184

3.5

1,582

19.6

Smoking Status

    

   Former

1,386

26.1

12,063

7.5

   Intermittent

627

11.8

5,403

10.2

   Current

3,307

62.2

28,342

12.5

Randomization Group

    

   Intervention, Ipratroprium

1,791

33.7

15,470

9.6

   Intervention, Placebo

1,770

33.3

15,271

10.5

   Control

1,759

33.1

15,067

12.7

Stage (pre-bronchodilator)*

    

   Stage 3 or 4

341

6.4

2,831

21.5

   Stage 2

3,587

67.4

30,875

11.3

   Stage 1

995

18.7

8,674

7.3

   Restricted

92

1.7

768

15.6

   Normal

305

5.7

2,659

5.6

Stage (post-bronchodilator)*

    

   Stage 3 or 4

183

3.4

1,475

29.8

   Stage 2

3,048

57.3

26,237

12.0

   Stage 1

1,242

23.3

10,775

7.2

   Restricted

126

2.4

1,059

13.2

   Normal

721

13.6

6,262

7.8

  1. *Modified chronic obstructive pulmonary disease stage, as defined in methods